The Godavari Biorefineries IPO was launched in October 2024 and attracted attention because the company operates in the bio-chemicals and ethanol sector, which is linked to India’s renewable energy and green chemicals growth story.
But the important question investors ask is simple: Was the Godavari Biorefineries IPO good or bad?
Let’s break it down step-by-step.
About Godavari Biorefineries
Godavari Biorefineries Limited is an integrated biorefinery company that manufactures ethanol-based chemicals, bio-based products, and specialty chemicals. The company has been operating for decades and is among the major producers of ethanol and related chemicals in India.
Its products are used in several industries:
- Pharmaceuticals
- Personal care products
- Food and flavoring ingredients
- Bio-chemicals
- Renewable fuels like ethanol
One unique feature of the company is that it produces bio-based chemicals derived from sugar and other renewable resources, which is a growing global industry.
Godavari Biorefineries IPO Details
Here are the key details of the IPO:
- IPO opening date: 23 October 2024
- IPO closing date: 25 October 2024
- Listing date: 30 October 2024
- Price band: ₹334 – ₹352 per share
- Lot size: 42 shares
- Minimum investment: about ₹14,784
- Issue size: about ₹554.75 crore
- Listing exchange: NSE and BSE
The IPO included:
- Fresh issue: ₹325 crore
- Offer for sale: ₹229.75 crore
The funds from the fresh issue were mainly intended for expansion and corporate purposes.
Subscription Demand
Investor response to the IPO was moderate, not extremely strong compared to many popular IPOs.
The overall subscription was around 1.77 times.
Breakdown included:
- QIB (institutional investors): about 2.7x
- Retail investors: about 1.6x
- NII investors: less than 1x
This level of demand usually suggests average investor interest.
Listing Performance
The IPO did not deliver listing gains.
- Issue price: ₹352
- Listing price: about ₹308–₹310
- Listing loss: roughly 12% for investors.
This means investors who bought the IPO and sold on listing day lost money.
Current Stock Performance
After listing, the stock continued to trade below the IPO price.
For example, in early 2026, the share price has been around ₹280–₹290, which is still lower than the IPO price.
From the listing price to the current level, the stock has declined further.
Strengths of Godavari Biorefineries
1. Growing Bio-Chemical Industry
The company operates in the bio-chemicals and renewable fuels sector, which is expected to grow due to global sustainability initiatives.
2. Diversified Product Portfolio
Godavari Biorefineries manufactures many types of bio-based chemicals used in pharmaceuticals, personal care, and food industries.
3. R&D and Innovation
The company has been working on advanced chemical compounds and even received patents for new pharmaceutical molecules.
This shows the company’s focus on research.
Risks and Weaknesses
1. Weak Listing Performance
The stock listed at a discount of about 12%, which disappointed many IPO investors.
2. Low Profit Margins
The company’s profit margin is very low (around 0.7%), indicating limited profitability.
3. Weak Financial Ratios
Financial indicators show concerns such as:
- Low return on capital
- Low return on equity
- Slow revenue growth
4. Moderate IPO Subscription
The IPO was subscribed less than 2 times overall, showing average demand.
Financial Snapshot
Key financial indicators include:
- Revenue around ₹1,900+ crore
- Profit around ₹20 crore
- Market cap around ₹1,300–1,400 crore
These numbers show the company is large in revenue but low in profitability.
Final Verdict – Is Godavari Biorefineries IPO Good or Bad?
Short answer: The Godavari Biorefineries IPO was not very good for short-term investors.
Positive Points
- Operates in renewable bio-chemical sector
- Diversified chemical products
- R&D and patent development
Negative Points
- Listing loss (around 12%)
- Weak profitability
- Low investor demand
- Stock still below IPO price
Overall Rating
5/10 – Average IPO with weak listing performance.
Short-term investors faced losses, while long-term investors need to wait for the company’s bio-chemical and ethanol business growth to see meaningful returns.
